SUPN · Supernus Pharmaceuticals, Inc.
$42.18
-0.86 (-2.00%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$2.48B
Shares
58.13M
Volume · Oct 1
424.63K
Avg daily vol (3M)
781.5K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$42.18
Open$43.21
Day$42.15–43.69
52W close$41.28–57.00
Avg vol 30d606K
Short int5.0M · 8.6% float · 8.7d
Short vol65%
Last earningsAug 3, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 4 wks
filed Aug 3, 2026
call held May 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-9.9%
Trailing year
Short interest
8.6%
Latest settlement · 8.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Moderate
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−13%
below
Price vs 50-day avg
−6%
below
RSI (14)
43
neutral
MACD trend
Positive
52-week position
6%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−17%
trailing
YTD return
−15%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $45 › 200d $48 — 200d above 50d
Institutional flow
Accumulating
+2% holders QoQ · +46 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.58% of float · ▲ +6.8% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
336 holders — near 3-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
−4%
Y/Y
EPS growth
−152%
Y/Y
Free cash flow
$46.0M
Balance sheet
$175.8M
net debt
Quant / Vol
risk profile
Volatility
36%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
3.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 3, 2026
ONAPGO net sales
· Full Year 2026
GAAP
Initiated
$55M – $70M
Trokendi XR and Oxtellar XR net sales
· Full Year 2026
GAAP
Initiated
$50M – $60M
Guided vs delivered
· last 2 settled
Total revenues
Full Year 2024
guided $580M – $620M
$661.82M
Beat +10.3%
Revenue
full year 2021
guided $550M – $570M
$579.78M
Beat +3.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−13%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
43
Neutral
MACD trend
Positive
Bullish
52-week position
6%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $45 › 200d $48 — 200d above 50d
Institutional flow
Accumulating
+2% holders QoQ · +46 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.58% of float · ▲ +6.8% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
336 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $41
Now $42 · 6%
Range high $57
vs 200-day avg -13%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SUPN
this stock
Supernus Pharmaceuticals, Inc.
|
$2.48B | -15.1% | -3.9% | — | 8.6% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.0% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.7% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SUPN | -2.6% | -4.2% | -16.8% | -2.0% | -15.1% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -2.1% | -4.1% | -29.2% | -2.2% | -27.2% |
Key facts
CIK
1356576
CUSIP
868459108
13F (30d)
12 filings
10 filers
Visit website
Investor relations